1.
2.
Occult HBV infection
by Raimondo, Giovanni
Seminars in immunopathology, 2012-07-26, Vol.35 (1), p.39-52
3.
Hepatitis B surface antigen seroprevalence among pre- and post-vaccine cohorts in Cambodia, 2017
by Ork, Vichit
Vaccine, 2019-08-14, Vol.37 (35), p.5059-5066
4.
Status and progress of hepatitis B control through vaccination in the South-East Asia Region, 1992–2015
by Childs, Lana
Vaccine, 2018-01-02, Vol.36 (1), p.6-14
5.
Identification and impact of hepatitis B virus DNA and antigens in pancreatic cancer tissues and adjacent non-cancerous tissues
by Jin, Yan
Cancer letters, 2013, Vol.335 (2), p.447-454
6.
Seroepidemiology of hepatitis B virus infection in 2 million men aged 21–49 years in rural China: a population-based, cross-sectional study
by Liu, Jue, PhD
The Lancet infectious diseases, 2016, Vol.16 (1), p.80-86
7.
Serological and molecular epidemiological outcomes after two decades of universal infant hepatitis B virus (HBV) vaccination in Nunavut, Canada
by Huynh, Chris
Vaccine, 2017-08-16, Vol.35 (35), p.4515-4522
8.
The global impact of vaccination against hepatitis B: A historical overview
by Zanetti, Alessandro R
Vaccine, 2008, Vol.26 (49), p.6266-6273
9.
10.
Hepatitis B core-related antigen (HBcrAg) levels in the natural history of hepatitis B virus infection in a large European cohort predominantly infected with genotypes A and D
by Maasoumy, B
Clinical microbiology and infection, 2015-06, Vol.21 (6), p.606.e1-606.e10
11.
Hepatitis B virus infection
by Liaw, Yun-Fan, Prof
The Lancet (British edition), 2009, Vol.373 (9663), p.582-592
12.
Higher proportion of viral basal core promoter mutant increases the risk of liver cirrhosis in hepatitis B carriers
by Tseng, Tai-Chung
Gut, 2015-02, Vol.64 (2), p.292-302
13.
Hepatitis B surface antibodies seroprevalence among people born before and after implementation of universal HBV vaccination
by Di Lello, Federico A
Vaccine, 2020-03-10, Vol.38 (12), p.2678-2682
14.
Post-vaccination serologic testing of infants born to hepatitis B surface antigen positive mothers in 4 provinces of China
by Wang, Fuzhen
Vaccine, 2017-07-24, Vol.35 (33), p.4229-4235
15.
A predictive value of quantitative HBsAg for serum HBV DNA level among HBeAg-positive pregnant women
by Sun, Kui-Xia
Vaccine, 2012, Vol.30 (36), p.5335-5340
16.
Chronic hepatitis B reactivation following infliximab therapy in Crohn’s disease patients: need for primary prophylaxis
by Esteve, M
Gut, 2004-09, Vol.53 (9), p.1363-1365
17.
Hepatitis B vaccine effectiveness in the face of global HBV genotype diversity
by Cassidy, Adrian
Expert review of vaccines, 2011-12-01, Vol.10 (12), p.1709-1715
18.
Adolescent booster with hepatitis B virus vaccines decreases HBV infection in high-risk adults
by Wang, Yuting
Vaccine, 2016, Vol.35 (7), p.1064-1070
19.
Hepatitis B virus-induced hepatocellular carcinoma
by Xu, Cheng
Cancer letters, 2013, Vol.345 (2), p.216-222
20.
The gamma-glutamyl transpeptidase to platelet ratio (GPR) predicts significant liver fibrosis and cirrhosis in patients with chronic HBV infection in West Africa
by Lemoine, Maud Maud
Gut, 2015-06-24, Vol.65 (8), p.1369-1376
